Sistema de Salut de Catalunya
Institut Català de la Salut
[Mesa RA] Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA. Atrium Health, Charlotte, NC, USA. Wake Forest University School of Medicine, Winston-Salem, NC, USA. [Harrison C] Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom. [Palmer JM] Mayo Clinic, Phoenix, AZ, USA. [Gupta V] Princess Margaret Cancer Centre, University of Toronto, ON, Canada. [McLornan DP] Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom. University College Hospital, London, United Kingdom. [McMullin MF] Queen’s University, Belfast, United Kingdom. [Fox ML] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2023-11-14T08:27:02Z
2023-11-14T08:27:02Z
2023-11
Patient-reported outcomes; Anemic; Myelofibrosis
Resultados informados por los pacientes; Anémicos; Mielofibrosis
Resultats informats pels pacients; Anèmics; Mielofibrosi
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm that typically manifests with debilitating symptoms that progressively worsen, negatively impacting patients’ quality of life. Fatigue is a multifactorial and burdensome MF-related symptom due to its severity, persistence, and prevalence, with anemia a contributing factor and major unmet need. Clinical trials of the Janus kinase (JAK)1/JAK2/activin A receptor type 1 inhibitor momelotinib have shown consistent anemia benefits, in addition to improvements in MF-related symptoms. The phase 3 MOMENTUM trial in symptomatic and anemic patients met its primary end point, with a greater proportion having a Myelofibrosis Symptom Assessment Form (MFSAF) Total Symptom Score (TSS) reduction ≥50% at week 24 with momelotinib versus danazol. To support the positive primary end point result, we conducted longitudinal, responder, and time-to-event analyses of patient-reported outcomes from MOMENTUM, as measured by the MFSAF, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), and Patient-Reported Outcomes Measurement Information System (PROMIS) assessments. These analyses demonstrated rapid and durable response benefits with momelotinib, with achievement of first TSS response by day 29 and continued improvement over time. Improvements favored momelotinib versus danazol for each MFSAF individual item, and greater improvements were observed for disease- and cancer-related fatigue and physical functioning at week 24, with significant results for multiple items/domains across the 3 assessments. These findings are consistent in demonstrating that momelotinib provides substantial symptom benefit.
This study was funded by Sierra Oncology, a GSK company.
Article
Published version
English
Qualitat de vida; Anèmia - Tractament; Mielofibrosi - Tractament; Medicaments antineoplàstics - Ús terapèutic; DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders; DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Anemia; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents; HEALTH CARE::Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life; ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::enfermedades de la médula ósea::trastornos mieloproliferativos; ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::anemia; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos de neoplasias; ATENCIÓN DE SALUD::ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida
Wolters Kluwer Health
HemaSphere;7(11)
http://dx.doi.org/10.1097/HS9.0000000000000966
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - HVH [3439]
